SoftwareArbour Group Sees Opportunity in 2009 Despite Economic Downturn
The demand for regulatory compliance services continues at a high level. This phenomenon is due to increased regulatory enforcement from the FDA and other global enforcement bodies.
OAKBROOK TERRACE, IL, January 28, 2009 /24-7PressRelease/ -- Arbour Group continues to see significant volatility among Life Sciences companies. The industry feedback we have gathered indicates continued economic turbulence for the first two quarters of 2009, with stabilization beginning in the third quarter. There continues to be consolidation within the industry. However, overall the trend of consolidation has slowed both domestically and internationally.
The demand for regulatory compliance services continues at a high level. This phenomenon is due to increased regulatory enforcement from the FDA and other global enforcement bodies. 2008 saw the launch of a local FDA office in China along with an emphasis on increased compliance enforcement for products being shipped into the United States.
Medical Device clients are anticipating strong demand for new treatments that will become available through advances in medical technology. The demographics of an aging population will also help support demand even in an economic slowdown.
Pharmaceutical manufacturers who are dependent on patent protection will continue to pursue the introduction of new drugs by funding product discovery and marketing efforts in the foreseeable future. These manufacturers will look to reduce costs elsewhere so as to protect their future product revenue streams. Pharmaceutical demand will also be supported by medical advances that will discover new cures for a larger array of diseases.
During the fourth quarter of 2008, there was a slowdown in the funding of new information technology projects. Though the need for the purchase and implementation of these technologies has not diminished, the tendency has been the deferral of approvals.
Arbour Group is addressing the trend to defer new information technology implementation by offering a set of services that allow customers to derive the maximum benefit from their compliance dollars. These service offerings are delivered by industry professionals at highly competitive rates. Consequently, adherence to regulatory guidelines is achieved in a cost effective manner. Contact us at info@arbourgroup.com for further information
Arbour Group President & CEO, Alexander Patterson, stated, "Life Sciences companies are looking for the highest value for their compliance investments. Arbour Group can provide a definitive roadmap for achieving adherence to regulatory agency requirements even at reduced spending levels."
Archie O"Leary, Vice President of Sales for Arbour Group, comments, "A number of clients rely on our compliance capabilities to outsource their entire validation and testing processes. We can deploy on site and/or Global Test Center resources at very competitive rates, thus allowing our clients the ability to redirect their staff to mission critical activities while maintaining an effective regulatory profile."
About Arbour Group
Arbour Group LLC is a leading provider of regulatory products and services for pharmaceutical, medical device and biotechnology companies worldwide.
Arbour Group"s regulatory products include packaged validation protocols that help clients ensure that key enterprise software solutions are functional and in compliance with applicable regulations to minimize business risk. Regulatory services are based on a results-oriented software testing process that not only assures compliance and functionality, but also responds competitively to the needs of customers by ensuring product quality and reliability.
The Arbour Advantage is the combination of offerings that are designed to help regulated companies harmonize compliance efforts across diverse business software systems, geographically dispersed facilities and complex regulatory environments.
Arbour Group has been lowering the cost of compliance since 1990 for over 100 multinational companies with a global presence including United States offices in California, Illinois, and New Jersey, along with facilities in Dublin, Ireland and Dubai, U.A.E.